AstraZeneca Could Have Used Outdated Information in Vaccine Trial
The British-Swedish drug will now work with US health authorities to provide updated efficacy data.
Grow your business,
Not your inbox
Stay up to date and subscribe to our daily newsletter now!
March 23, 2021 2 min read
Contrary to previous news that AstraZeneca’s Covid vaccine is effective in the US, the country’s health authorities are now saying the Anglo-Swedish pharmaceutical company may have used “out of date information” to draw a conclusion, reports ABC News.
The Data and Safety Monitoring Board – a collective of experts overseeing the National Institute of Dental and Craniofacial Research division of the US National Institutes of Health (NIH) – has raised concerns that the UK-based pharmaceutical company has not provided a complete picture his data. The company announced on Monday that its vaccine would protect adults of all ages with a 79% effectiveness rate against symptomatic cases.
Related topics: Thanks to mRNA technology, Moderna developed a Covid-19 vaccine in just two days
As previously reported, AstraZeneca had released partial results of late-stage testing on more than 32,000 US adult participants. The results reportedly showed a 100% success rate in shielding against hospitalizations and deaths related to Covid. The company should file for FDA approval of the vaccine in early April.
According to the Washington Post, Anthony S. Fauci, director of the National Institute of Allergies and Infectious Diseases at the NIH, tried to address concerns about the recent board revelation, claiming that AstraZeneca’s shot “is very likely a good vaccine.”
In response to the board’s findings, AstraZeneca said it would work with health officials “immediately” to provide the most up-to-date efficacy data, the Post added.
So far, the federal government has only given the green light to the distribution of Johnson & Johnson, Pfizer, and Moderna vaccines.